The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High- Risk Donor Type

被引：0
|
作者：
Dadwal, Sanjeet S. [1 ]
Yang, Dongyun [2 ]
Marcucci, Guido [3 ]
Mokhtari, Sally [4 ]
Tegtmeier, Bernard [5 ]
Palmer, Joycelynne [6 ]
Smith, Eileen P. [7 ]
Taplitz, Randy [1 ]
Artz, Andrew S. [8 ]
Curtin, Peter T. [7 ]
Spielberger, Ricardo [7 ,9 ]
Salhotra, Amandeep [7 ]
Stein, Anthony S. [10 ]
Forman, Stephen J. [11 ]
Al Malki, Monzr M. [7 ]
Nakamura, Ryotaro [12 ]
机构：
[1] City Hope Natl Med Ctr, Div Infect Dis, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Computat & Quantitat Med, 1500 E Duarte Rd, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Beckman Res Inst, Dept Hematol Malignancies Translat Sci, Gehr Family Ctr Leukemia Res,Hematol Malignancies, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Dept Clin Translat Program Dev, 1500 E Duarte Rd, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Dept Qual Risk & Regulatory Management, 1500 E Duarte Rd, Duarte, CA 91010 USA
[6] City Hope Natl Med Ctr, Dept Computat & Quantitat Med BRI, 1500 E Duarte Rd, Duarte, CA 91010 USA
[7] City Hope Natl Med Ctr, Dept Hematol HCT, 1500 E Duarte Rd, Duarte, CA 91010 USA
[8] City Hope Natl Med Ctr, Dept Hematol HCT, Duarte, CA USA
[9] Southern Calif Kaiser Permanente, Bone Marrow Transplant Program, Los Angeles, CA USA
[10] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[11] City Hope Natl Med Ctr, Beckman Res Inst, Dept Hematol HCT, Duarte, CA USA
[12] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153784
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1776
引用
收藏
页码：1776 / +
页数：6
相关论文
共 50 条
  • [41] Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint
    Solh, Melhem
    Zhang, Xu
    Connor, Katelin
    Brown, Stacey
    Morris, Lawrence E.
    Holland, H. Kent
    Bashey, Asad
    Solomon, Scott R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (12) : 2192 - 2198
  • [42] Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial
    Yoav Golan
    Yuexin Tang
    Shahrul Mt-Isa
    Hong Wan
    Valerie Teal
    Cyrus Badshah
    Sanjeet Dadwal
    PharmacoEconomics - Open, 2021, 5 : 469 - 473
  • [43] Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial
    Golan, Yoav
    Tang, Yuexin
    Mt-Isa, Shahrul
    Wan, Hong
    Teal, Valerie
    Badshah, Cyrus
    Dadwal, Sanjeet
    PHARMACOECONOMICS-OPEN, 2021, 5 (03) : 469 - 473
  • [44] Incidence of and Risk Factors for Cytomegalovirus (CMV), Epstein Barr Virus (EBV) and Adenovirus (ADV) Reactivation in Pediatric Recipients Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHCT)
    Rustia, Evelyn
    Violago, Leah
    Jin, Zhezhen
    Bhatia, Monica
    Kung, Andrew
    Foca, Marc
    George, Diane
    Garvin, James
    Satwani, Prakash
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S84 - S85
  • [45] Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes
    Huang, Yao-Ting
    Su, Yiqi
    Kim, Seong Jin
    Nichols, Paige
    Burack, Daniel
    Maloy, Molly
    Giralt, Sergio
    Perales, Miguel-Angel
    Jakubowski, Ann A.
    Papanicolaou, Genovefa A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (04) : 791 - 799
  • [46] Impact of natural killer cell reconstitution on outcomes in patients with early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation
    Kanamori, Heiwa
    Ando, Taiki
    Ishiyama, Yasufumi
    Tachibana, Takayoshi
    Tanaka, Masatsugu
    Nakajima, Hideaki
    BONE MARROW TRANSPLANTATION, 2019, 54 : 429 - 430
  • [47] Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
    Vyas, Ami
    Raval, Amit D.
    Kamat, Shweta
    LaPlante, Kerry
    Tang, Yuexin
    Chemaly, Roy F.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (01):
  • [48] A Real-World Efficacy of Letermovir Primary Prophylaxis for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation in China: A Single-Center Retrospective Analysis
    Zhang, Xiaoyu
    Yang, Donglin
    Pang, Aiming
    He, Yi
    Wei, Jialin
    Zhang, Rongli
    Zhai, Weihua
    Ma, Qiaoling
    Chen, Xin
    Han, Mingzhe
    Feng, Sizhou
    Jiang, Erlie
    BLOOD, 2023, 142
  • [49] Letermovir for Prevention of Cytomegalovirus Infection in Chinese Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Phase 3, Open-Label, Single-Arm Trial
    He, Yun
    Xu, Lanping
    Dong, Yujun
    Song, Xianmin
    Zhang, Yicheng
    Jiang, Erlie
    Yu, Hu
    Lin, Ren
    Wang, Ying
    Guo, Xiaodan
    Zhao, Weiwei
    Badshah, Cyrus
    BLOOD, 2024, 144 : 7302 - 7303
  • [50] Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis
    Esteve, Marina
    Albert, Eliseo
    Gimenez, Estela
    Colomer, Ester
    Hernandez-Boluda, Juan Carlos
    Hernani, Rafael
    Pinana, Jose Luis
    Solano, Carlos
    Navarro, David
    BONE MARROW TRANSPLANTATION, 2024, 59 (10) : 1480 - 1482
12345